Published May 10, 2026 CBD Products Are Everywhere — But That Has Not Solved Hemp Farming Problems CBD products remain widely visible across the United States and parts of Europe in 2026. Oils, beverages, gummies, capsules, skincare products, and hemp-derived cannabinoid products continue appearing in wellness stores, smoke shops, pharmacies, and online marketplaces. From theContinue reading “Why Hemp Farmers Are Still Struggling Even as CBD Products Remain Popular”
Category Archives: CBD & Hemp
Explore in-depth coverage of CBD, hemp regulation, and the evolving market for hemp-derived cannabinoid products. This section tracks policy changes, product innovation, and industry trends affecting CBD, Delta-8, hemp-derived THC, and other cannabinoids produced from federally legal hemp.
As lawmakers refine testing standards, licensing requirements, and product safety rules, CBD & Hemp coverage examines how regulatory shifts influence manufacturers, retailers, and consumers. From compliance changes and labeling standards to emerging product categories and wellness market expansion, this section analyzes how hemp continues evolving within the broader cannabis economy.
What This Category Covers
Within CBD & Hemp, readers will find reporting and analysis on topics such as:
Federal and state hemp regulatory updates
CBD product compliance and testing standards
Hemp-derived THC and minor cannabinoid developments
Consumer safety and labeling requirements
Market growth trends and retail expansion
Industry responses to shifting enforcement priorities
As hemp-derived cannabinoids become more integrated into mainstream retail and wellness markets, this category provides insight into the policies, products, and industry forces shaping the sector’s future.
Latest CBD & Hemp News
↓
Faster-Acting CBD Products Are Reshaping Consumer Expectations in 2026
Published May 4, 2026 A Shift Toward Faster Effects Is Taking Hold CBD products have evolved quickly, but one issue has remained consistent: unpredictable onset time. Many consumers still report that traditional CBD products take too long to work or feel inconsistent from one use to the next. In 2026, that problem is driving aContinue reading “Faster-Acting CBD Products Are Reshaping Consumer Expectations in 2026”
EU Sets Low CBD Intake Limit, Highlighting Global Divide Over Hemp Regulation
Published April 30, 2026 Europe’s New CBD Intake Limit Is Lower Than Expected European regulators have introduced one of the most conservative CBD intake thresholds to date, signaling a cautious approach that contrasts sharply with other global markets. The European Food Safety Authority (EFSA) has proposed a provisional safe intake level of approximately 0.0275 mgContinue reading “EU Sets Low CBD Intake Limit, Highlighting Global Divide Over Hemp Regulation”
Why CBD Is Suddenly Back in the Federal Spotlight (April 2026 Update)
Published April 25, 2026 CBD Returns to the Center of Federal Policy Discussions Cannabidiol (CBD) is once again at the center of federal cannabis policy discussions in 2026. While much of the national attention has focused on marijuana rescheduling, recent developments have shifted part of that focus toward CBD and hemp-derived products. This renewed attentionContinue reading “Why CBD Is Suddenly Back in the Federal Spotlight (April 2026 Update)”
CBD Product Labels Face New Scrutiny as Accuracy Concerns Grow in 2026
Published April 20, 2026 Label Accuracy Is Becoming a Bigger CBD Story CBD regulation has dominated headlines for months, but a more practical issue is gaining momentum in 2026: whether product labels actually match what is inside the package. As federal agencies revisit compliance and oversight, label accuracy is moving closer to the center ofContinue reading “CBD Product Labels Face New Scrutiny as Accuracy Concerns Grow in 2026”
Minor Cannabinoids Gain Momentum as CBD Market Evolves in 2026
Published April 14, 2026 The CBD Market Is Shifting Beyond a Single Compound For years, CBD dominated the hemp conversation. It was the primary focus of products, marketing, and consumer awareness. That is starting to change. In 2026, the CBD market is expanding beyond a single cannabinoid. Consumers are becoming more interested in the broaderContinue reading “Minor Cannabinoids Gain Momentum as CBD Market Evolves in 2026”
Hemp Farmers Face Declining Prices as CBD Market Stabilizes in 2026
Published April 8, 2026 Hemp Farming Faces New Challenges in 2026 Hemp farming in 2026 is entering a new phase. After years of rapid expansion, the market is stabilizing. This shift is creating new challenges for growers across the United States. Prices for hemp biomass have declined in many regions. Supply now exceeds demand inContinue reading “Hemp Farmers Face Declining Prices as CBD Market Stabilizes in 2026”
Federal Health Program Opens Limited Access Path for Hemp-Derived CBD Products in 2026
Published April 2, 2026 New federal guidance gives the hemp and CBD market a major policy development to watch for The hemp and CBD industry received a major federal update this week, after the U.S. Food and Drug Administration issued a memo that clears the way for qualifying hemp-derived CBD products to be furnished throughContinue reading “Federal Health Program Opens Limited Access Path for Hemp-Derived CBD Products in 2026”
U.S. Hemp-Derived THC Products Face Increasing Regulation in 2026
Published March 28, 2026 States move to restrict Delta-8 and similar cannabinoids as legal gray areas shrink Hemp-derived THC products are facing increasing regulation across the United States in 2026, as lawmakers move to address legal gray areas created by the 2018 Farm Bill. Products such as Delta-8, Delta-10, and other hemp-derived cannabinoids have grownContinue reading “U.S. Hemp-Derived THC Products Face Increasing Regulation in 2026”
FDA Continues Crackdown on CBD Companies Making Unproven Health Claims
Published March 20, 2026 Federal regulators warn businesses against marketing CBD products with medical benefits The U.S. Food and Drug Administration (FDA) is continuing its enforcement efforts against CBD companies that market products with unproven health claims. Regulators say many businesses are still promoting cannabidiol as a treatment for serious medical conditions without sufficient evidence.Continue reading “FDA Continues Crackdown on CBD Companies Making Unproven Health Claims”